Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Gu et al., 2017
In a formal review, the agency concluded that BPC-157: Lacks sufficient safety data and has not been shown to be safe or effective in humans FDA Compounding Memorandum, 2023 The FDA also lists BPC-157 as ineligible for 503B compounding , which prohibits it from being added to compounded medications by outsourcing facilities
Out of these, eight participants were administered adjunctive EGb (240 mg/day) over a four-week duration, while the remaining eight continued solely with trimipramine monotherapy
Future studies should employ stratified analyses or doseresponse curves to explore the influence of different GSH doses on prognosis, offering guidance for more precise clinical application
